BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) saw some unusual options trading on Tuesday. Investors bought 14,691 call options on the stock. This represents an increase of approximately 454% compared to the typical daily volume of 2,654 call options.
BridgeBio Pharma Price Performance
Shares of BridgeBio Pharma stock traded down $1.32 during trading hours on Tuesday, reaching $24.08. The company had a trading volume of 1,875,276 shares, compared to its average volume of 1,873,597. BridgeBio Pharma has a one year low of $21.62 and a one year high of $44.32. The business has a fifty day simple moving average of $26.45 and a 200 day simple moving average of $27.13. The firm has a market cap of $4.51 billion, a PE ratio of -7.46 and a beta of 1.07.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.61. The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $3.96 million. During the same period in the previous year, the business earned ($0.98) earnings per share. BridgeBio Pharma’s revenue was up 32.1% on a year-over-year basis. On average, research analysts forecast that BridgeBio Pharma will post -2.49 EPS for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Analysis on BBIO
Insider Activity at BridgeBio Pharma
In related news, CEO Neil Kumar sold 27,389 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $676,234.41. Following the sale, the chief executive officer now owns 4,897,443 shares in the company, valued at approximately $120,917,867.67. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Neil Kumar sold 27,389 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total transaction of $676,234.41. Following the transaction, the chief executive officer now directly owns 4,897,443 shares of the company’s stock, valued at approximately $120,917,867.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Brian C. Stephenson sold 4,155 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total value of $102,586.95. Following the transaction, the chief financial officer now directly owns 85,192 shares in the company, valued at $2,103,390.48. The disclosure for this sale can be found here. Insiders have sold a total of 5,831,544 shares of company stock worth $150,128,821 in the last 90 days. Corporate insiders own 24.66% of the company’s stock.
Hedge Funds Weigh In On BridgeBio Pharma
A number of large investors have recently made changes to their positions in BBIO. Bfsg LLC raised its position in shares of BridgeBio Pharma by 175.6% in the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock worth $31,000 after buying an additional 790 shares in the last quarter. YHB Investment Advisors Inc. purchased a new stake in shares of BridgeBio Pharma in the first quarter worth $34,000. Headlands Technologies LLC purchased a new stake in shares of BridgeBio Pharma in the second quarter worth $48,000. Quarry LP purchased a new stake in shares of BridgeBio Pharma in the fourth quarter worth $50,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of BridgeBio Pharma in the first quarter worth $117,000. 99.85% of the stock is owned by institutional investors.
About BridgeBio Pharma
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Featured Articles
- Five stocks we like better than BridgeBio Pharma
- Why Invest in High-Yield Dividend Stocks?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What is the Shanghai Stock Exchange Composite Index?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.